12 research outputs found
Prevalence of pulmonary embolism among patients hospitalized for syncope
BACKGROUNDThe prevalence of pulmonary embolism among patients hospitalized for syncope is not well documented, and current guidelines pay little attention to a diagnostic workup for pulmonary embolism in these patients.METHODSWe performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative explanations for the syncope. The diagnosis of pulmonary embolism was ruled out in patients who had a low pretest clinical probability, which was defined according to the Wells score, in combination with a negative D-dimer assay. In all other patients, computed tomographic pulmonary angiography or ventilation-perfusion lung scanning was performed.RESULTSA total of 560 patients (mean age, 76 years) were included in the study. A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patients (58.9%) on the basis of the combination of a low pretest clinical probability of pulmonary embolism and negative D- dimer assay. Among the remaining 230 patients, pulmonary embolism was identified in 97 (42.2%). In the entire cohort, the prevalence of pulmonary embolism was 17.3% (95% confidence interval, 14.2 to 20.5). Evidence of an embolus in a main pulmonary or lobar artery or evidence of perfusion defects larger than 25% of the total area of both lungs was found in 61 patients. Pulmonary embolism was identified in 45 of the 355 patients (12.7%) who had an alternative explanation for syncope and in 52 of the 205 patients (25.4%) who did not.CONCLUSIONSPulmonary embolism was identified in nearly one of every six patients hospitalized for a first episode of syncope
Idraparinux: review of its clinical efficacy and safety for prevention andtreatment of thromboembolic disorders.
1. Expert Opin Investig Drugs. 2008 May;17(5):773-7.
Idraparinux: review of its clinical efficacy and safety for prevention and
treatment of thromboembolic disorders.
Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L.
Department of Medical and Surgical Sciences, Thromboembolism Unit, University of
Padua, 35128 - Padua, Italy. [email protected]
BACKGROUND: Idraparinux is a synthetic pentasaccharide that binds to antithrombin
with high affinity. In view of its long half-life, it is suitable for once-a-week
administration.
OBJECTIVE: To review the evidence favoring the use of idraparinux for the acute
and long-term treatment of patients with venous thromboembolism (VTE) and for the
prevention of thromboembolic events in patients with atrial fibrillation (AF).
METHODS: All preclinical and clinical studies carried out with the use of
idraparinux were sought through electronic searches of MEDLINE from January 1,
1999 up to December 31, 2007.
RESULTS: The administration of idraparinux in subcutaneous fixed doses of 2.5 mg
once weekly was found to be as effective and safe as conventional antithrombotic
therapy in the initial treatment of patients with deep vein thrombosis, but less
effective than standard therapy in the initial treatment of patients with primary
pulmonary embolism. During a 6-month extension of thromboprophylaxis, idraparinux
was effective in preventing recurrent VTE but was associated with an increased
risk of bleeding versus placebo. Finally, in patients with AF the long-term
treatment with idraparinux was as effective as vitamin K antagonists, but caused
more bleeding.
CONCLUSIONS: In its current formulation, idraparinux can be recommended only for
the initial treatment of patients with deep vein thrombosis. The bioequipotency
of a biotinylated version of idraparinux (idrabiotaparinux), whose effects can be
reversed by a neutralizing agent (avidin), is under investigation in the
treatment of VTE at present, as is the use of lower doses in patients with AF.
PMID: 18447601 [PubMed - indexed for MEDLINE
The Risk of Cancer Progression in Women With Gynecological Malignancies and Thrombophilic Polymorphisms: A Pilot Case-Control Study.
Clin Appl Thromb Hemost. 2009 Oct;15(5):535-9. Epub 2008 Jun 29.
The risk of cancer progression in women with gynecological malignancies and
thrombophilic polymorphisms: a pilot case-control study.
Tormene D, Beltramello P, Perlati M, Brandolin B, Barbar S, De Toffoli G, Simioni
P.
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine,
University of Padua Medical School, Padua, Italy. [email protected]
Cancer produces a hypercoagulable state, which might lead to thrombosis, and on
contrary, unprovoked venous thromboembolism might be the manifestation of an
occult cancer. In this pilot case-control study, we assessed the risk of
gynecological malignant diseases related to the presence of the factor V Leiden
and prothrombin G20210A polymorphisms. Fifty-two women underwent an operation for
gynecological malignancy and were enrolled in the study. Women who underwent an
operation for gynecological nonmalignant disease in the same days of cases were
considered as controls. The presence of factor V Leiden and prothrombin G20210A
was assessed in case and control groups. In all, 7 out of 52 cases were carriers
of the 2 polymorphisms compared with 20 out of 198 controls (odds ratio = 1.3;
95% confidence interval, 0.6-3.0). The results were also similar when the risk
was considered separately for the site of cancer. As for advanced and metastatic
malignancies, the odds ratios were 2.3 (95% confidence interval, 0.9-6.0) and 3.3
(95% confidence interval, 1.0-11), respectively, compared to noncancer patients.
When these 2 groups were compared to nonadvanced cancer group, the odds ratios
for carriers of polymorphisms were 2.7 (95%confidence interval, 0.7-11.0) and 3.9
(95%confidence interval, 0.8-18.6) for advanced cancer and metastatic
malignancies, respectively. Women with factor V Leiden or prothrombin G20210A
polymorphisms who developed gynecological malignancy might present with a higher
stage of cancer at the time of surgery. Larger case-control studies in similar
cohort of patients are needed to confirm these findings.
PMID: 18591179 [PubMed - indexed for MEDLINE
The Risk of Cancer Progression in Women With Gynecological Malignancies andThrombophilic Polymorphisms: A Pilot Case-Control Study.
Clin Appl Thromb Hemost. 2009 Oct;15(5):535-9. Epub 2008 Jun 29.
The risk of cancer progression in women with gynecological malignancies and
thrombophilic polymorphisms: a pilot case-control study.
Tormene D, Beltramello P, Perlati M, Brandolin B, Barbar S, De Toffoli G, Simioni
P.
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine,
University of Padua Medical School, Padua, Italy. [email protected]
Cancer produces a hypercoagulable state, which might lead to thrombosis, and on
contrary, unprovoked venous thromboembolism might be the manifestation of an
occult cancer. In this pilot case-control study, we assessed the risk of
gynecological malignant diseases related to the presence of the factor V Leiden
and prothrombin G20210A polymorphisms. Fifty-two women underwent an operation for
gynecological malignancy and were enrolled in the study. Women who underwent an
operation for gynecological nonmalignant disease in the same days of cases were
considered as controls. The presence of factor V Leiden and prothrombin G20210A
was assessed in case and control groups. In all, 7 out of 52 cases were carriers
of the 2 polymorphisms compared with 20 out of 198 controls (odds ratio = 1.3;
95% confidence interval, 0.6-3.0). The results were also similar when the risk
was considered separately for the site of cancer. As for advanced and metastatic
malignancies, the odds ratios were 2.3 (95% confidence interval, 0.9-6.0) and 3.3
(95% confidence interval, 1.0-11), respectively, compared to noncancer patients.
When these 2 groups were compared to nonadvanced cancer group, the odds ratios
for carriers of polymorphisms were 2.7 (95%confidence interval, 0.7-11.0) and 3.9
(95%confidence interval, 0.8-18.6) for advanced cancer and metastatic
malignancies, respectively. Women with factor V Leiden or prothrombin G20210A
polymorphisms who developed gynecological malignancy might present with a higher
stage of cancer at the time of surgery. Larger case-control studies in similar
cohort of patients are needed to confirm these findings.
PMID: 18591179 [PubMed - indexed for MEDLINE
The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study.
BACKGROUND:
The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied.
OBJECTIVE:
In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE).
METHODS:
Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers.
RESULTS:
One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95% CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95% CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status.
CONCLUSIONS:
Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation
The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study
The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. J Thromb Haemost. 2007 Nov;5(11):2193-6.
BACKGROUND:
The relationship between the G20210A prothrombin variant (PT-G20210A) and adverse pregnancy outcome has been studied by several groups in the last few years. However, because of the different design and sample sizes of these studies the estimated risks have varied.
OBJECTIVE:
In this retrospective, multi-center, cohort study we assessed the risk of thromboembolic or obstetric complications in women belonging to families of probands with isolated PT-G20210A and that were symptomatic for venous thromboembolism (VTE).
METHODS:
Two hundred and eighty-three female family members that had been pregnant at least once were enrolled. The occurrence of VTE and obstetric complications during pregnancy and postpartum were assessed in carriers of PT-G20210A and compared with non- carriers.
RESULTS:
One thromboembolic event occurred during the postpartum period in the carriers group. In the same group, 48 out of 359 pregnancies resulted in unexplained fetal loss as compared with 50 out of 357 pregnancies in the non-carriers (RR 0.9; 95% CI: 0.7-1.4). After adjustment, carriers of PT-G20210A showed a trend towards a higher risk of late fetal loss as compared with non-carriers (RR 2.2; 95% CI: 0.8-6.2). Furthermore, in pregnancies subsequent to those with previous fetal loss there was not a different risk of adverse outcome regardless of the carrier status.
CONCLUSIONS:
Female family members who are heterozygous carriers of isolated PT-G20210A do not seem to be at significant increased risk for fetal loss as compared with non-carriers. Screening for PT-G20210A of fertile age women belonging to these families is not warranted in this situation
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
BACKGROUND:
Prophylaxis of venous thromboembolism (VTE) in hospitalized medical patients is largely underused. We sought to assess the value of a simple risk assessment model (RAM) for the identification of patients at risk of VTE.
METHODS:
In a prospective cohort study, 1180 consecutive patients admitted to a department of internal medicine in a 2-year period were classified as having a high or low risk of VTE according to a predefined RAM. They were followed-up for up to 90 days to assess the occurrence of symptomatic VTE complications. The primary study outcome was to assess the adjusted hazard ratio (HR) of VTE in high-risk patients who had adequate in-hospital thromboprophylaxis in comparison with those who did not, and that of VTE in the latter group in comparison with low-risk patients.
RESULTS:
Four hundred and sixty-nine patients (39.7%) were labelled as having a high risk of thrombosis. VTE developed in four of the 186 (2.2%) who received thromboprophylaxis, and in 31 of the 283 (11.0%) who did not (HR of VTE, 0.13; 95% CI, 0.04-0.40). VTE developed also in two of the 711 (0.3%) low-risk patients (HR of VTE in high-risk patients without prophylaxis as compared with low-risk patients, 32.0; 95% CI, 4.1-251.0). Bleeding occurred in three of the 186 (1.6%) high-risk patients who had thromboprophylaxis.
CONCLUSIONS:
Our RAM can help discriminate between medical patients at high and low risk of VTE. The adoption of adequate thromboprophylaxis in high-risk patients during hospitalization leads to longstanding protection against thromboembolic events with a low risk of bleeding